Trial Profile
A placebo controlled, randomized, prospective phase II trial of sivelestat for the treatment of lung injury in surgery for congenital heart disease with pulmonary hypertension
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2015
Price :
$35
*
At a glance
- Drugs Sivelestat (Primary)
- Indications Lung injury
- Focus Therapeutic Use
- 06 Nov 2015 New trial record